In biomarker, small Peninsula biotech hopes to find answers to ALS
Neuraltus Pharmaceuticals Inc. is taking an experimental drug against amyotrophic lateral sclerosis, or Lou Gehrig's disease, into a second mid-stage trial, guided by a previous study that suggested that patients with a specific protein biomarker would respond best.
The 120-patient study by the Palo Alto company is an important one for ALS patients and caregivers who have been frustrated by a handful of failed clinical flameouts of potential ALS drugs. Only one drug, riluzole, is approved for the...